$ADMA
ADMA Biologics Inc

2023 Q2 Form 10-Q Financial Statement

#000114036123023920 Filed on May 10, 2023

View on sec.gov

Income Statement

Concept 2023 Q2 2023 Q1 2022 Q1
Revenue $60.12M $56.91M $29.10M
YoY Change 77.33% 95.56% 81.34%
Cost Of Revenue $43.43M $40.40M $25.44M
YoY Change 66.18% 58.8% 43.17%
Gross Profit $16.69M $16.51M $3.662M
YoY Change 114.82% 350.92% -312.72%
Gross Profit Margin 27.76% 29.01% 12.58%
Selling, General & Admin $14.25M $14.51M $13.70M
YoY Change 19.02% 5.93% 36.53%
% of Gross Profit 85.37% 87.88% 374.1%
Research & Development $1.403M $855.4K $624.1K
YoY Change 60.67% 37.05% -36.81%
% of Gross Profit 8.41% 5.18% 17.04%
Depreciation & Amortization $1.900M $1.900M $1.400M
YoY Change 26.67% 35.71% 27.27%
% of Gross Profit 11.38% 11.51% 38.23%
Operating Expenses $17.16M $17.33M $18.48M
YoY Change 1.29% -6.23% 37.45%
Operating Profit -$473.1K -$813.3K -$14.82M
YoY Change -94.84% -94.51% -2.3%
Interest Expense $6.299M $6.115M $3.389M
YoY Change 37.75% 80.45% 6.05%
% of Operating Profit
Other Income/Expense, Net -$5.898M -$5.975M -$10.19M
YoY Change 28.48% -41.38% 216.97%
Pretax Income -$6.371M -$6.789M -$25.01M
YoY Change -53.72% -72.85% 36.06%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$6.371M -$6.789M -$25.01M
YoY Change -53.72% -72.85% 36.06%
Net Earnings / Revenue -10.6% -11.93% -85.93%
Basic Earnings Per Share -$0.03 -$0.03 -$0.13
Diluted Earnings Per Share -$0.03 -$0.03 -$0.13
COMMON SHARES
Basic Shares Outstanding 222.3M 222.2M 195.9M
Diluted Shares Outstanding 222.7M 221.9M 195.9M

Balance Sheet

Concept 2023 Q2 2023 Q1 2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $62.51M $69.20M $69.50M
YoY Change 19.27% -0.43% 12.1%
Cash & Equivalents $62.51M $69.20M $69.50M
Short-Term Investments
Other Short-Term Assets $5.219M $4.379M $5.519M
YoY Change -3.36% -20.67% -4.84%
Inventory $161.8M $164.0M $139.1M
Prepaid Expenses
Receivables $36.73M $26.52M $25.63M
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $266.2M $264.1M $239.8M
YoY Change 19.51% 10.13% 35.25%
LONG-TERM ASSETS
Property, Plant & Equipment $56.31M $57.37M $53.22M
YoY Change 2.46% 7.8% 20.47%
Goodwill $3.500M $3.530M
YoY Change -0.84%
Intangibles $655.7K $834.6K
YoY Change -52.17%
Long-Term Investments
YoY Change
Other Assets $6.289M $4.719M $2.826M
YoY Change 67.44% 66.99% 28.44%
Total Long-Term Assets $76.78M $76.70M $68.23M
YoY Change 3.54% 12.41% 16.9%
TOTAL ASSETS
Total Short-Term Assets $266.2M $264.1M $239.8M
Total Long-Term Assets $76.78M $76.70M $68.23M
Total Assets $343.0M $340.8M $308.0M
YoY Change 15.52% 10.63% 30.71%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $12.08M $12.96M $14.12M
YoY Change 6.12% -8.21% 15.7%
Accrued Expenses $27.53M $21.59M $14.22M
YoY Change 103.75% 51.81% 75.55%
Deferred Revenue $142.8K $142.8K
YoY Change 0.0%
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $41.95M $36.73M $31.57M
YoY Change 49.45% 16.35% 48.9%
LONG-TERM LIABILITIES
Long-Term Debt $140.3M $144.3M $138.4M
YoY Change 0.36% 4.25% 48.2%
Other Long-Term Liabilities $449.5K $338.7K $11.11M
YoY Change 20.22% -96.95% 26374.11%
Total Long-Term Liabilities $449.5K $338.7K $149.5M
YoY Change 20.22% -99.77% 356227.68%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.95M $36.73M $31.57M
Total Long-Term Liabilities $449.5K $338.7K $149.5M
Total Liabilities $196.3M $195.1M $181.1M
YoY Change 7.52% 7.75% 47.04%
SHAREHOLDERS EQUITY
Retained Earnings -$491.2M -$484.8M
YoY Change 8.94%
Common Stock $22.45K $22.23K
YoY Change 14.35%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $146.8M $145.7M $126.9M
YoY Change
Total Liabilities & Shareholders Equity $343.0M $340.8M $308.0M
YoY Change 15.52% 10.63% 30.71%

Cashflow Statement

Concept 2023 Q2 2023 Q1 2022 Q1
OPERATING ACTIVITIES
Net Income -$6.371M -$6.789M -$25.01M
YoY Change -53.72% -72.85% 36.06%
Depreciation, Depletion And Amortization $1.900M $1.900M $1.400M
YoY Change 26.67% 35.71% 27.27%
Cash From Operating Activities -$6.059M -$14.72M -$26.01M
YoY Change -52.78% -43.41% -21.72%
INVESTING ACTIVITIES
Capital Expenditures $872.6K $1.945M $2.842M
YoY Change -122.15% -31.58% 10.54%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$872.6K -$1.945M -$2.842M
YoY Change -77.85% -31.58% 10.54%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 240.1K -650.5K 47.27M
YoY Change -175.26% -101.38% 12.97%
NET CHANGE
Cash From Operating Activities -6.059M -14.72M -26.01M
Cash From Investing Activities -872.6K -1.945M -2.842M
Cash From Financing Activities 240.1K -650.5K 47.27M
Net Change In Cash -6.691M -17.32M 18.42M
YoY Change -60.85% -194.04% 204.67%
FREE CASH FLOW
Cash From Operating Activities -$6.059M -$14.72M -$26.01M
Capital Expenditures $872.6K $1.945M $2.842M
Free Cash Flow -$6.931M -$16.67M -$28.86M
YoY Change -22.04% -42.24% -19.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2022Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
77738022
CY2022Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2023Q1 us-gaap Goodwill Impairment Loss
GoodwillImpairmentLoss
0
CY2022Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1400000
CY2022Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2023Q1 us-gaap Amortization Of Intangible Assets
AmortizationOfIntangibleAssets
200000
CY2023Q1 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
78655947
CY2023Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6669941
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.03
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.03
CY2022Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.13
CY2022Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.13
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
221921750
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
221921750
CY2022Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
195871932
CY2022Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
195871932
CY2023Q1 adma Number Of Plasma Collection Facilities Under Development
NumberOfPlasmaCollectionFacilitiesUnderDevelopment
10
CY2023Q1 adma Number Of Fda Licensed Plasma Collection Facilities
NumberOfFDALicensedPlasmaCollectionFacilities
8
CY2023Q1 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
100000
CY2022Q4 us-gaap Goodwill
Goodwill
3500000
CY2023Q1 us-gaap Goodwill
Goodwill
3500000
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
P4Y
CY2023Q1 us-gaap Inventory Raw Materials
InventoryRawMaterials
55747754
CY2022Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
48644527
CY2023Q1 us-gaap Inventory Work In Process
InventoryWorkInProcess
62087760
CY2022Q4 us-gaap Inventory Work In Process
InventoryWorkInProcess
56170853
CY2023Q1 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
834577
CY2022Q4 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5007467
CY2022Q4 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
3994052
CY2022Q4 us-gaap Finite Lived Intangible Assets Net
FiniteLivedIntangibleAssetsNet
1013415
CY2023Q1 us-gaap Inventory Finished Goods
InventoryFinishedGoods
46149359
CY2022Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
58464667
CY2023Q1 us-gaap Inventory Net
InventoryNet
163984873
CY2022Q4 us-gaap Inventory Net
InventoryNet
163280047
CY2023Q1 us-gaap Finite Lived Intangible Assets Gross
FiniteLivedIntangibleAssetsGross
5007467
CY2023Q1 us-gaap Finite Lived Intangible Assets Accumulated Amortization
FiniteLivedIntangibleAssetsAccumulatedAmortization
4172890
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year
FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear
536514
CY2023Q1 us-gaap Finite Lived Intangible Assets Amortization Expense Next Rolling Twelve Months
FiniteLivedIntangibleAssetsAmortizationExpenseNextRollingTwelveMonths
298063
CY2023Q1 adma Working Capital
WorkingCapital
227400000
CY2023Q1 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
69200000
CY2023Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
28346315
CY2023Q1 dei Amendment Flag
AmendmentFlag
false
CY2023Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2023Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2023
CY2023Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2023Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001368514
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
151974215
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1110166
CY2023Q1 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
-640946
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
0
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6788815
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
145654620
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
141172566
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
9569604
CY2022Q1 us-gaap Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition
AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
1641388
CY2022Q1 adma Vesting Of Restricted Stock Units Net Of Shares Withheld For Taxes And Retired Amount
VestingOfRestrictedStockUnitsNetOfSharesWithheldForTaxesAndRetiredAmount
-442636
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25007857
CY2022Q1 us-gaap Stockholders Equity
StockholdersEquity
126933065
CY2023Q1 adma Number Of Fda Approved Product
NumberOfFDAApprovedProduct
3
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
300000000
CY2023Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 adma Accounts Receivable Allowance For Contractual Credits And Doubtful Accounts
AccountsReceivableAllowanceForContractualCreditsAndDoubtfulAccounts
100000
CY2023Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q1 us-gaap Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
0
CY2022Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
19476541
CY2023Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
57370783
CY2022Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
58261481
CY2023Q1 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1900000
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
222262588
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
221816930
CY2023Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
48356592
CY2023Q1 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
29380820
CY2022Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
27047033
CY2023Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Award Requisite Service Period1
ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
P10Y
CY2022Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2023Q1 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
0
CY2022Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2023Q1 us-gaap Unrecognized Tax Benefits Period Increase Decrease
UnrecognizedTaxBenefitsPeriodIncreaseDecrease
0
CY2023Q1 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
21285164
CY2023Q1 adma Accrued Rebates Current
AccruedRebatesCurrent
13129902
CY2022Q4 adma Accrued Rebates Current
AccruedRebatesCurrent
11436484
CY2023Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
4406033
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
3166896
CY2023Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1179600
CY2022Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
4193919
CY2023Q1 adma Accrued Testing Current
AccruedTestingCurrent
169825
CY2022Q4 adma Accrued Testing Current
AccruedTestingCurrent
309867
CY2023Q1 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
1745245
CY2022Q4 us-gaap Accrued Salaries Current
AccruedSalariesCurrent
4086379
CY2023Q1 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
2041859
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
1795804
CY2023Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
22672464
CY2022Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24989349
CY2023Q1 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
155727724
CY2022Q4 adma Senior Notes Payable Before Debt Discount
SeniorNotesPayableBeforeDebtDiscount
154747746
CY2023Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
11426794
CY2022Q4 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
11914683
CY2023Q1 us-gaap Senior Long Term Notes
SeniorLongTermNotes
144300930
CY2022Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
142833063
CY2022Q1 us-gaap Debt Instrument Unamortized Discount
DebtInstrumentUnamortizedDiscount
13900000
CY2022Q4 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2023Q1 us-gaap Preferred Stock Capital Shares Reserved For Future Issuance
PreferredStockCapitalSharesReservedForFutureIssuance
10000000
CY2023Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2023Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2022Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q1 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.99
CY2022Q4 us-gaap Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
1.99
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1110166
CY2022Q1 us-gaap Share Based Compensation
ShareBasedCompensation
1641388
CY2023Q1 adma Number Of Fda Licensed Plasma Collection Facilities Approved
NumberOfFDALicensedPlasmaCollectionFacilitiesApproved
5
CY2021 adma Number Of Fda Inspections
NumberOfFDAInspections
2
CY2023Q1 adma Plasma Supply Agreement Term
PlasmaSupplyAgreementTerm
P10Y
CY2023Q1 adma Plasma Purchased
PlasmaPurchased
11600000
CY2023Q1 adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.40
CY2022Q1 adma Plasma Purchased
PlasmaPurchased
15500000
CY2022Q1 adma Percentage Of Inventory Purchases
PercentageOfInventoryPurchases
0.75
CY2019Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1500000
CY2023Q1 adma Number Of Remaining Plasma Collection Facilities Under Construction
NumberOfRemainingPlasmaCollectionFacilitiesUnderConstruction
10
CY2023Q1 adma Number Of Fda Licensed Plasma Collection Facilities
NumberOfFDALicensedPlasmaCollectionFacilities
8
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56913534
CY2023Q1 us-gaap Cost Of Revenue
CostOfRevenue
40400544
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-813318
CY2023Q1 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-5975497
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-6788815
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1944596
CY2023Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
2032965
CY2023Q1 us-gaap Assets
Assets
340787542
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29103093
CY2022Q1 us-gaap Cost Of Revenue
CostOfRevenue
25441046
CY2022Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-14815066
CY2022Q1 adma Interest And Other Nonoperating Income Expense
InterestAndOtherNonoperatingIncomeExpense
-3522850
CY2022Q1 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-6669941
CY2022Q1 us-gaap Net Income Loss
NetIncomeLoss
-25007857
CY2022Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2842085
CY2022Q1 us-gaap Depreciation And Amortization
DepreciationAndAmortization
1590217
CY2022Q1 us-gaap Assets
Assets
308032492
CY2023Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
56913534
CY2022Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
29103093
CY2023Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2022Q1 us-gaap Operating Lease Expense
OperatingLeaseExpense
400000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
600000
CY2022Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
400000
CY2023Q1 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
11400000
CY2022Q4 adma Operating And Financing Lease Liability
OperatingAndFinancingLeaseLiability
11600000
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P8Y3M18D
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
1805644
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
2343314
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
2366432
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
2116036
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
2040690
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
2087825
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
6150746
CY2023Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
18910687
CY2023Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
7486533
CY2023Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
956045
CY2023Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
10468109
CY2023Q1 us-gaap Interest Paid Net
InterestPaidNet
4639283
CY2022Q1 us-gaap Interest Paid Net
InterestPaidNet
2525987
CY2023Q1 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
530434
CY2022Q1 adma Equipment Acquired Reflected In Accounts Payable And Accrued Liabilities
EquipmentAcquiredReflectedInAccountsPayableAndAccruedLiabilities
1940425
CY2023Q1 adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
0
CY2022Q1 adma Warrants Issued In Connection With Notes Payable
WarrantsIssuedInConnectionWithNotesPayable
9569604

Files In Submission

Name View Source Status
FilingSummary.xml Edgar Link unprocessable
0001140361-23-023920-index-headers.html Edgar Link pending
0001140361-23-023920-index.html Edgar Link pending
0001140361-23-023920.txt Edgar Link pending
0001140361-23-023920-xbrl.zip Edgar Link pending
adma-20230331.xsd Edgar Link pending
brhc20052583_10q.htm Edgar Link pending
brhc20052583_ex31-1.htm Edgar Link pending
brhc20052583_ex31-2.htm Edgar Link pending
brhc20052583_ex32-1.htm Edgar Link pending
brhc20052583_ex32-2.htm Edgar Link pending
adma-20230331_cal.xml Edgar Link unprocessable
adma-20230331_def.xml Edgar Link unprocessable
adma-20230331_lab.xml Edgar Link unprocessable
adma-20230331_pre.xml Edgar Link unprocessable
brhc20052583_10q_htm.xml Edgar Link completed
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending